Oral Oncology
Volume 38, Issue 1 , Pages 41-48 , January 2002

Bcl-xL confers multi-drug resistance in several squamous cell carcinoma cell lines

  • T. Noutomi

      Affiliations

    • Department of Oral & Maxillofacial-Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • ,
  • H. Chiba

      Affiliations

    • Department of Oral & Maxillofacial-Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • ,
  • M. Itoh

      Affiliations

    • Department of Oral & Maxillofacial-Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • ,
  • H. Toyota

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • Intractable Disease Research Center, Tokyo Medical University, Tokyo, Japan
    • ,
  • J. Mizuguchi

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • Intractable Disease Research Center, Tokyo Medical University, Tokyo, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-3-3351-6141; fax: +81-3-3341-2941

Received 13 July 2000 ,Accepted 4 September 2000.

References 

  1. Niitani H, Kobayashi K. Cisplatin/Carboplatin therapy in non-small cell lung cancer. Oncology. 1992;49(Suppl 1):51–56
  2. Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue (high response rate for refractory ovarian carcinoma). Journal of Clinical Oncology. 1994;12:176–183
  3. Zamboglou N, Schnabel T, Kolotas C, Achterrath W, Strehl H, Dalhauser S, et al. Carboplatin and radiotherapy in the treatment of head and neck cancer (six years' experience). Seminars in Oncology. 1994;21:45–53
  4. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends in Biochemical Siences. 1995;20:435–439
  5. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthemia. Biochemical Pharmacology. 1990;40:2353–2362
  6. Felice VD, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. International Journal of Oncology. 1998;13:225–232
  7. Yanase N, Takada E, Yoshihama I, Ikegami H, Mizuguchi J. Participation of Bax-α in IFN-αmediated apoptosis in Daudi B lymphoma cells. Journal of Interferon and Cytokine Research. 1998;18:855–861
  8. Raff MC. Social controls on cell survival and cell death. Nature. 1992;356:397–400
  9. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462
  10. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 1985;229:1390–1393
  11. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Medicine. 1997;3:614–620
  12. Adams JM, Cory S. The Bcl-2 protein family (arbiters of cell survival). Science. 1998;281:1322–1326
  13. Chao DT, Korsmeyer SJ. Bcl-2 family (regulators of cell death). Annual Review of Immunology. 1998;16:395–419
  14. Reed JC. Bcl-2 family proteins. Oncology. 1998;17:3225–3236
  15. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoid and multiple chemotherapeutic drugs. Cancer Research. 1992;52:5407–5411
  16. Simonian PL, Grillot DAM, Nunez G. Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death. Blood. 1997;90:1208–1216
  17. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, et al. Induction of the death-promoting gene bax-αsensitizes cultured breast-cancer cells to drug-induced apoptosis. International Journal of Cancer. 1996;67:138–141
  18. Guo B, Cao S, Toth K, Azrak RG, Rustum YM. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clinical Cancer Research. 2000;718-724:718–724
  19. Levine AJ. p53, the cellular gate keeper for growth and division. Cell. 1997;88:323–331
  20. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G. p53 expression and cell proliferation in squamous cell carcinomas of head and neck. Cancer. 1995;75:87–93
  21. Hirvikoski P, Kumpulaninen E, Virtaniemi J, Johansson R, Haapasalo H, Marin S, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carconoma. Journal of Clinical Oncology. 1997;15:3111–3120
  22. Gallagher WM, Cairnney M, Schott B, Roninson IB, Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene. 1997;14:185–193
  23. Song K, Cowan KH, Sinha BK. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncology Research. 1999;11:153–159
  24. Minagawa Y, Kigawa J, Itamochi H, Kanamori Y, Shimada M, Takahashi M, et al. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Japanese Journal of Cancer Research. 1999;90:1373–1379
  25. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumor cell lines. International Journal of Cancer. 1997;73:592–599
  26. Eastman A. Mechanisms of resistance to cisplatin. Kluwer Academic Publishers: Boston; 1991;
  27. Itoh M, Chiba H, Noutomi T, Takada E, Mizuguchi J. Cleavage of Bax-α and Bcl-xL during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncology. 2000;36:277–285
  28. Hermanek P, Hunter RVP, Sobin LH, Wagner G, Wittekind C. TNM Atals. 4th ed. Springer, 1997.
  29. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 1997;44:1299–1305
  30. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships (the combined effects of multiple drugs or enzyme inhibitors). Advances in Enzyme Regulation. 1984;22:27–55
  31. Mizuguchi J, Yamanashi Y, Ehara K, Tamura T, Nariuchi H, Gyotoku Y, et al. Tyrosine protein kinase is involved in anti-IgM-mediated signaling in BAL17 B lymphoma cells. The Journal of Immunology. 1992;148:689–694
  32. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, et al. Allelotype of breast cancer (cumulative allele losses promote tumor progression in primary breast cancer). Cancer Recearch. 1990;50:7184–7189
  33. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989;5:874–879
  34. Boise LH, Gonzalez-Garcia M, Postema CE, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597–608
  35. Reed JC. Mechanism of apoptosis avoidance in cancer. Current Opinion in Oncology. 1999;11:68–75
  36. Kojima H, Endo K, Moriyama H, Tanaka Y, Alnemri ES, Slapak CA, et al. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. The Journal of Biological Chemistry. 1998;273:16647–16650
  37. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceeding nuclear apoptosis induced by chemotherapeutic agents. Cancer Research. 1997;57:62–67
  38. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53
  39. Deimling Av, Eibl RH, Ohgaki H, Louis DN, Ammon Kv, Petersen I, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Research. 1992;52:2987–2990
  40. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Research. 1992;52:3674–3678
  41. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents — Is the bullet really magical?. Science. 1993;261:1004–1012
  42. Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochemica et Biophysica ACTA. 1999;1489:97–106

PII: S1368-8375(00)00098-1

Oral Oncology
Volume 38, Issue 1 , Pages 41-48 , January 2002

Article Tools

* Image Usage & Resolution